[
  {
    "ts": "2026-02-11T05:35:06+00:00",
    "headline": "The 5 Most Interesting Analyst Questions From AbbVie’s Q4 Earnings Call",
    "summary": "AbbVie’s fourth quarter results came in above Wall Street’s revenue and profit expectations, but the market responded negatively, reflecting concerns over certain business segments and future headwinds. Management attributed the quarter’s performance to robust growth in its immunology and neuroscience franchises, especially from SKYRIZI, RINVOQ, and Vraylar. Meanwhile, ongoing declines in HUMIRA due to biosimilar competition and continued softness in the aesthetics segment tempered overall resul",
    "url": "https://finance.yahoo.com/news/5-most-interesting-analyst-questions-053506214.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "7e9be687-eb67-3430-8dc9-5a45da20d470",
      "content": {
        "id": "7e9be687-eb67-3430-8dc9-5a45da20d470",
        "contentType": "STORY",
        "title": "The 5 Most Interesting Analyst Questions From AbbVie’s Q4 Earnings Call",
        "description": "",
        "summary": "AbbVie’s fourth quarter results came in above Wall Street’s revenue and profit expectations, but the market responded negatively, reflecting concerns over certain business segments and future headwinds. Management attributed the quarter’s performance to robust growth in its immunology and neuroscience franchises, especially from SKYRIZI, RINVOQ, and Vraylar. Meanwhile, ongoing declines in HUMIRA due to biosimilar competition and continued softness in the aesthetics segment tempered overall resul",
        "pubDate": "2026-02-11T05:35:06Z",
        "displayTime": "2026-02-11T05:35:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "ABBV Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/K222hrzb0FJJlqrDZzsz7w--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cD3IChyAhZhexmnMXW7jMA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/5-most-interesting-analyst-questions-053506214.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-most-interesting-analyst-questions-053506214.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]